Harlan Laboratories Announces Invenium Pharmacology as Agent for Southeast Asia, Australia and New Zealand

ITINGEN, Switzerland--Harlan Laboratories, Ltd., a privately held provider of general and specialty toxicology services, announces the appointment of Invenium Pharmacology as its exclusive agent for Harlan's Contract Research Services (CRS) in Australia, Southeast Asia and New Zealand.

Through the agency agreement, Harlan CRS will strengthen its local presence in the pharmaceutical and chemicalindustries across the region. Anthony Bishop of Invenium Pharmacology will take on the primary contact role in the region.

With more than 15 years of experience in pharmaceutical companies and contract research organizations, Bishop brings extensive experience in business development, global project management and sales to Harlan CRS.

As the local agent for Harlan CRS, Bishop will provide leadership and management expertise to connect drug development companies with the services and insight they need to advance their programs. This agreement also positions Harlan CRS for continued growth on a global scale.

"There are great growth opportunities for Harlan CRS in this region," said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. "Working with Anthony Bishop and Invenium Pharmacology, we can provide the expertise that companies and organizations in this region need — at a local level."

About Harlan Laboratories, Ltd.

Harlan Laboratories, Ltd., a subsidiary of Harlan Laboratories, Inc., provides general and specialty toxicology services through its Contract Research Services business to the global chemical, agrochemical and pharmaceutical industries. With laboratory locations in Germany, Spain, Switzerland and the UK, Harlan and its affiliates are focused on providing customers with services to optimize product development. Please visitwww.Harlan.com/CRS.



For Harlan Laboratories, Ltd.
Lea Studer, +1 308-237-5567
[email protected]


Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.